Iovance falls after U.S. FDA puts hold on lung cancer therapy trial

Iovance Biotherapeutics

27/12/2023 12:26

** Shares of Iovance Biotherapeutics  IOVA.O  fall 26.3% to
$6.55 premarket
    ** Co says the U.S. FDA has placed a clinical hold on its
trial on a therapy for a type of lung cancer, after a patient's
death
    ** IOVA will stop enrollment into the trial and will
continue to monitor patients treated with the therapy
    ** Up to Tuesday's close, stock up 39.1% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))